| Pharmaceutical Information |
| Drug Name |
Macitentan |
| Drug ID |
BADD_D01336 |
| Description |
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension.[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. |
| Indications and Usage |
Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.[L39105, L39105] |
| Marketing Status |
approved |
| ATC Code |
C02KX04 |
| DrugBank ID |
DB08932
|
| KEGG ID |
D10135
|
| MeSH ID |
C533860
|
| PubChem ID |
16004692
|
| TTD Drug ID |
D0S7JH
|
| NDC Product Code |
65015-872; 11722-058; 66215-501; 68225-070; 69037-0030; 76397-014; 59651-122; 82245-0117; 69766-006 |
| UNII |
Z9K9Y9WMVL
|
| Synonyms |
macitentan | N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide | ACT 064992 | ACT064992 | ACT-064992 | Actelion-1 | opsumit |
|
| Chemical Information |
| Molecular Formula |
C19H20Br2N6O4S |
| CAS Registry Number |
441798-33-0 |
| SMILES |
CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
